Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Launches TruSight™ Tumor Content Set

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Enables somatic variant detection in solid tumors using next-generation sequencing (NGS).

Illumina, Inc. has announced the next product in its TruSight line of content sets, TruSight Tumor, for NGS-based somatic variant detection in solid tumors.

TruSight Tumor provides optimized amplicon-based library preparation of 26 oncogenes and tumor suppressor genes selected for their involvement in common solid tumors, including lung, colon, melanoma, gastric, and ovarian cancer.

TruSight Tumor also offers a comprehensive NGS-based tumor profiling solution that provides a broader and more cost-effective view of tumor heterogeneity compared to genotyping-based methods.

Researchers can simultaneously detect somatic changes in multiple genes across the tumor genome, as referenced in industry guidelines, as well as emerging biomarkers implicated in pharmaceutical clinical trials.

Designed for use with formalin-fixed paraffin-embedded (FFPE) samples, TruSight Tumor enables high levels of sensitivity for minor allele detection (below 5%), with limited DNA input requirements.

“TruSight Tumor is designed to run on Illumina’s industry-leading sequencing platforms and enables clinical researchers to understand the molecular heterogeneity of FFPE tumor samples,” said Matt Posard, Senior Vice President and General Manager of Illumina’s Translational and Consumer Genomics business.

Posard continued, “This technology has the potential to expand candidates for targeted therapies who may otherwise be missed with single variant or single gene approaches.”

“Tumor characterization using next-generation sequencing enables clinical research laboratories to gain a deeper understanding of underlying biology. In order to detect clinically relevant variants, it is important to look beyond single genes or hotspot mutations while achieving very low levels of sensitivity," said Dr. Robert Daber, Technical Director of Clinical Genomics, Center for Personalized Diagnostics, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania.

TruSight Tumor is the first content set designed for somatic variant detection on the Illumina MiSeq® platform.

As a portfolio, TruSight content sets are designed for high performance targeted sequencing to meet the specific needs of the clinical research laboratory by providing high analytical sensitivity and specificity.

They offer exceptional performance in the capture and sequencing of targeted genomic regions, and are selected through collaborations with experts from leading institutions.

TruSight content sets are for research use only and not intended for diagnostic use. TruSight Tumor is now available for order with shipment expected in Q2’13.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Accelerator Welcomes First International Fellow
Illumina Accelerator has expanded their startup pool with the Center of Individualized Diagnostics (CID).
Wednesday, August 24, 2016
Illumina Applauds FDA’s Issuance of Draft Guidances
Company has supported the FDA in their efforts to provide a flexible and streamlined approach to the oversight of NGS diagnostic test.
Friday, July 08, 2016
ArcherDX, Illumina Launch Collaboration
Agreement to bring multiple Archer® assays through the FDA approval process.
Tuesday, May 31, 2016
Illumina Registers MiSeqDx System in South Korea
Regulatory milestone clears path for clinical laboratories to use Illumina NGS technology.
Tuesday, May 10, 2016
Illumina Files Patent Infringement Suit against Genoma SA
Company has announced that it has filed a patent infringement suit against Genoma SA in the Switzerland for Infringement of NIPT Patents.
Friday, April 22, 2016
Illumina Invests In New Venture Fund
Illumina will commit $100M over 10 years to drive genomic technology development.
Friday, April 15, 2016
Illumina Applies CE Mark to VeriSeq™ NIPT Analysis Software
Company has announced that it has applied the CE mark to expand the use of VeriSeq NIPT analysis software in clinical laboratories.
Thursday, February 25, 2016
Illumina Sues Oxford Nanopore for Patent Infringement
Illumina, Inc. has announced that the company filed lawsuits against Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies, Inc. (ONT).
Wednesday, February 24, 2016
Genomics England, Illumina Enter Bioinformatics Partnership
Illumina, and Genomics England have announced a partnership to develop a platform and knowledge base that can be used to improve and automate genome interpretation.
Thursday, February 11, 2016
Illumina Signs Multiple Biobank Deals
MEGA array family and next-generation sequencing to support comprehensive genomics approach toward personalized medicine.
Wednesday, February 03, 2016
Illumina Appoints Dr. Frances Arnold to Its Board of Directors
Illumina, Inc. has announced that Dr. Frances Arnold has joined the company’s Board of Directors. Dr. Arnold manages a research group at the California Institute of Technology and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center.
Thursday, January 28, 2016
Illumina Acquires Conexio Genomics
Acquisition strengthens company’s ability to deliver sample-to-report solutions for HLA typing.
Wednesday, January 27, 2016
Bio-Rad, Illumina Partner
Scalable, high-throughput platform to offer unprecedented insight into gene expression of individual cells.
Tuesday, January 12, 2016
Illumina Launches Cancer Screening Company
Formation of GRAIL seen as a significant development in the war on cancer.
Monday, January 11, 2016
Novogene and Illumina Enters into Agreement
Agreement to co-develop NGS diagnostic system for reproductive health and oncology applications.
Wednesday, December 16, 2015
Scientific News
NASA's DNA Sequencing in Space is a Success
DNA has been sequenced in space for the first time ever for the Biomolecule Sequencer investigation, using the MinION sequencing device.
New Inflammatory Disease Discovered
NIH researchers have discovered a rare and potentially deadly disease - otulipenia - the mostly affects children.
Bringing NGS to the Crime Lab
New technology being validated in BCI lab for use in Ohio missing persons cases.
Expanding Knowledge of Viral Diversity
Environmental datasets help researchers double the number of microbial phyla known to be infected by viruses.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
The Power of Model Systems
New insights into the influence of host on the gut microbiome are revealed with in situ light sheet fluorescence microscopy and stochastic mathematical modelling.
New Way To Measure Important Chemical Modification On RNA
Technology could advance stem cells’ use in regenerative medicine, UCLA researchers say.
Mapping Antibody Creation in Humans
Researchers have created the first, detailed map of the body's antibody production, which could suggest new treatment options for immune disorders.
Decoding the Genome of the Olive Tree
A team of scientists from three Spanish centers has sequenced, for the first time ever, the complete genome of the olive tree. This work will facilitate genetic improvement for production of olives and olive oil, two key products in the Spanish economy and diet.
Four Newly-Identified Genes Could Improve Rice
A Japanese research team have applied a method used in human genetic analysis to rice and rapidly discovered four new genes that are potentially significant for agriculture. These findings could influence crop breeding and help combat food shortages caused by a growing population.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!